Project Details
Description
The PI's laboratory has recently discovered a novel, soluble truncated
form of the receptor encoded by the proto-oncogene c-erbBI.(1-2)
Preliminary data from the PI's laboratory and others suggest that the
related proto-oncogenes, c-erbB2 and c-erbB3, also encode soluble
receptor forms. (3-6) The c-erbB family of proto-oncogenes has been
implicated in the development of both breast and ovarian carcinomas. In
this application, we hypothesize that soluble forms of receptors encoded
by the c-erbB family of proto-oncogenes may be important in ovarian
carcinogenesis and mav have clinical utility as markers of disease
activity, as prognostic indicators, and/or as potential targets for
future therapeutic approaches. To test this hypothesis we propose to
measure the serum levels of soluble forms of c-erbB receptors in a large
cohort of women with advanced ovarian cancer. We will compare the
expression of soluble receptors in serum with c-erbB expression in tumor
cells as determined by immunohistochemical analysis. We will then
compare c-erbB patterns of expression (in sera and tumor samples) with
established histologic and clinical parameters. We also propose to
delineate the molecular basis for the synthesis of soluble c-erbB
receptor forms in ovarian tumors, and will test the ability of these
soluble receptors to inhibit ovarian carcinoma cell growth in vitro.
form of the receptor encoded by the proto-oncogene c-erbBI.(1-2)
Preliminary data from the PI's laboratory and others suggest that the
related proto-oncogenes, c-erbB2 and c-erbB3, also encode soluble
receptor forms. (3-6) The c-erbB family of proto-oncogenes has been
implicated in the development of both breast and ovarian carcinomas. In
this application, we hypothesize that soluble forms of receptors encoded
by the c-erbB family of proto-oncogenes may be important in ovarian
carcinogenesis and mav have clinical utility as markers of disease
activity, as prognostic indicators, and/or as potential targets for
future therapeutic approaches. To test this hypothesis we propose to
measure the serum levels of soluble forms of c-erbB receptors in a large
cohort of women with advanced ovarian cancer. We will compare the
expression of soluble receptors in serum with c-erbB expression in tumor
cells as determined by immunohistochemical analysis. We will then
compare c-erbB patterns of expression (in sera and tumor samples) with
established histologic and clinical parameters. We also propose to
delineate the molecular basis for the synthesis of soluble c-erbB
receptor forms in ovarian tumors, and will test the ability of these
soluble receptors to inhibit ovarian carcinoma cell growth in vitro.
Status | Finished |
---|---|
Effective start/end date | 8/1/92 → 5/31/00 |
Funding
- National Institutes of Health
ASJC
- Medicine(all)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.